← Leaderboards
Mary E Hamby
Cognition Therapeutics, Inc.
$9,832,688
Attributed
$29,498,064
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.8M · FY2021–23$20M$15M$10M$5M$0
'21
'22
'23
Funding mix
By agency
NIH$29,498,064 · 1
By mechanism
R01$29,498,064 · 1
Top collaborators
- Anthony O Caggiano3 shared
- James E Galvin3 shared
Most similar at Cognition Therapeutics, Inc.
Same institution · by research overlap
- Paul S. Aisen$209,920,520
- Anthony O Caggiano$51,394,003
- Susan M Catalano$36,630,926
- Nicholas John Izzo$4,437,830
- Christopher H Van Dyck$43,230,259
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAdverse EventCerebrospinal Fluid ProteinsBiological MarkersAmyloid Beta-ProteinAutopsyBindingBinding SitesClinical TreatmentBiologyBrainCell MembraneCenters Of Research ExcellenceCerebrospinal FluidAlpha SynucleinClinical CandidateClinical DevelopmentClinical EfficacyActivities Of Daily LivingClinical TrialsCognitionCognitiveCognitive FunctionAbeta Oligomer
Grant awards (3)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$8,479,107
R01 · FY2023 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,254,288
R01 · FY2022 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,764,669
R01 · FY2021 · AG